Company · seqirus-6295d3ee

Seqirus

4 sourcescompanies-2026-11-14-0.1.0

Cite this record

ConductScience Library. Seqirus. Companies, record seqirus-6295d3ee. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/seqirus-6295d3ee

On this page

Company

The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.

Name: Seqirus
Trials: 61
As lead sponsor: 53
As collaborator: 8
Recruiting: 1
Active, recruiting or not: 2
Completed: 56
Stopped early, withdrawn or suspended: 2
Posted results: 35
Trials by phase: Phase 1 8, Phase 2 17, Phase 3 21, Phase 4 10
Drugs its trials test: 2
Comparisons calculated in its trials: 34
First trial registered: 2005-08-29
Last update: 2026-09-21

Source ClinicalTrials.gov

Pipeline2

The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.

Drug	Highest phase registered	Trials	As lead sponsor	Recruiting	Targets	Mechanism	In Drugs and targets	Source
INFLUENZA VIRUS VACCINE	Phase 4	12	12	0			https://conductscience.org/library/drugs/CHEMBL2109042	Open Targets
TOZINAMERAN	Phase 2	1	0	0			https://conductscience.org/library/drugs/CHEMBL4650429	Open Targets

Trials61

The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.

Trial	Title	Role	Phase	Status	Type	Participants	Start	Results first posted	Drugs	In Trials	Source
NCT07390968	Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients	Collaborator	Phase 2	Not yet recruiting	Interventional	56	2026-12-01		TOZINAMERAN	https://conductscience.org/library/trials/NCT07390968	ClinicalTrials.gov
NCT06279871	Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults	Collaborator	Phase 3	Completed	Interventional	1,514	2024-03-27	2025-12-12		https://conductscience.org/library/trials/NCT06279871	ClinicalTrials.gov
NCT06125691	Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults	Collaborator	Phase 1	Completed	Interventional	139	2024-01-22			https://conductscience.org/library/trials/NCT06125691	ClinicalTrials.gov
NCT06087640	A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age	Lead sponsor	Phase 3	Completed	Interventional	38,769	2023-10-23			https://conductscience.org/library/trials/NCT06087640	ClinicalTrials.gov
NCT06029933	Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years	Collaborator		Recruiting	Observational	1,500,000	2023-08-17			https://conductscience.org/library/trials/NCT06029933	ClinicalTrials.gov
NCT06028347	Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults	Lead sponsor	Phase 1	Completed	Interventional	96	2023-10-05			https://conductscience.org/library/trials/NCT06028347	ClinicalTrials.gov
NCT06015282	The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older	Lead sponsor	Phase 3	Completed	Interventional	7,741	2023-11-03			https://conductscience.org/library/trials/NCT06015282	ClinicalTrials.gov
NCT05875961	Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults	Lead sponsor	Phase 1	Completed	Interventional	600	2023-06-15		INFLUENZA VIRUS VACCINE	https://conductscience.org/library/trials/NCT05875961	ClinicalTrials.gov
NCT05874713	Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults	Lead sponsor	Phase 2	Completed	Interventional	480	2023-06-07			https://conductscience.org/library/trials/NCT05874713	ClinicalTrials.gov
NCT05501561	Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age	Lead sponsor	Phase 2	Completed	Interventional	1,056	2022-08-25	2026-06-30		https://conductscience.org/library/trials/NCT05501561	ClinicalTrials.gov

1 to 10 of 61

See all 61 trials

Conditions26

The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.

Condition	Trials
Influenza	30
Influenza, Human	25
Virus Diseases	4
Infections	3
Respiratory Tract Infections	3
Birth Defect	2
Human	2
Infection Viral	2
Influenza Caused by the Novel Influenza A (H1N1) Virus	2
Influenza-like Illness	2

1 to 10 of 26Source ClinicalTrials.gov

See all 26 conditions

Partners12

The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.

Organization	Class	Trials shared	In Companies	Source
Novartis Vaccines	Industry	7	https://conductscience.org/library/companies/novartis-vaccines-ff190280	ClinicalTrials.gov
Arcturus Therapeutics, Inc.	Industry	3	https://conductscience.org/library/companies/arcturus-therapeutics-inc-18c92b0f	ClinicalTrials.gov
Biomedical Advanced Research and Development Authority	US federal	3		ClinicalTrials.gov
Insight Therapeutics, LLC	Other	3		ClinicalTrials.gov
Brown University	Other	2		ClinicalTrials.gov
Case Western Reserve University	Other	2		ClinicalTrials.gov
Novotech (Australia) Pty Limited	Industry	2	https://conductscience.org/library/companies/novotech-australia-pty-limited-7b937c87	ClinicalTrials.gov
Community and Patient Preference Research Pty Ltd	Industry	1	https://conductscience.org/library/companies/community-and-patient-preference-research-pty-ltd-2623882b	ClinicalTrials.gov
Fred Hutchinson Cancer Center	Other	1		ClinicalTrials.gov
Glenmark Pharmaceuticals S.A.	Industry	1	https://conductscience.org/library/companies/glenmark-pharmaceuticals-s-a-b7038c44	ClinicalTrials.gov

1 to 10 of 12

See all 12 partners

Data dates

The date of each source this release read.

Sponsors and results posted: 2026-11-14; ClinicalTrials.gov
Trials' registrations: 2026-11-12; ClinicalTrials.gov
Drug links and targets: 2026-09-18; Open Targets
Comparisons: 2026-03-23; Trial comparisons

Sources 4

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL
ClinicalTrials.govNo license stated
Open TargetsCC0 1.0

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this company from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/companies/v1/seqirus-6295d3ee

GET https://conductscience.org/api/companies/v1/seqirus-6295d3ee/trials?page=2

API reference For AI assistants